Previous 10 | Next 10 |
Natera (NASDAQ: NTRA ) has priced its public offering of 5,263,158 common shares at $19.00 per share. More news on: Natera, Inc., Healthcare stocks news, Read more ...
SAN CARLOS, Calif. , April 17, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $19.00 per share. Clos...
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 of shares of its common stock. In addition, Natera expects to grant t...
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), Cancer Research UK , Imperial College London and the University of Leicester , today announced the publication of results of a clinical study demonstrating that the Signatera...
CareDx ( CDNA +4.4% ) has filed a second lawsuit against Natera ( NTRA +3.7% ) accusing it of misleading doctors and patients about its kidney transplant technology compared to CDNA's AlloSure via its "false advertising campaign" claiming that its technology is superior to AlloSure. ...
SAN CARLOS, Calif. , April 10, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing (WES) of circulating tumor DNA, using plasma samples from p...
The Federal Reserve Board and the Federal Deposit Insurance Corp. say they didn't identify any deficiencies or weaknesses in the 2017 resolution plans, known as "living wills," for the 14 financial institutions evaluated. More news on: Natera, Inc., Ally Financial Inc., American Express ...
SAN CARLOS, Calif. , March 28, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage determination (LCD) for use of the company's new Prospera donor-derived cell-free D...
Natera ( NTRA +0.7% ) perks up on light volume on the heels of its announced collaboration with AML Therapeutics in a clinical trial evaluating the latter's therapeutic cancer vaccine candidate ATP128 in patients with stage IV colorectal cancer. More news on: Natera, Inc., Healthcare s...
SAN CARLOS, Calif. , March 26, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical tri...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...